Michael Tuscan

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases – on its agreement to sell to Bristol Myers Squibb. Barbara Borden, Marya Postner and Rowook Park led the Cooley team advising Forbius. 

Cooley advised Iconic Therapeutics on the closing of its $40 million Series C financing. The round included new investors HBM Healthcare Investments, Cormorant Asset Management and Osage University Partners. All of Iconic's existing investors, including MPM Capital, H.I.G. Capital and Lundbeck fund Ventures, participated in the round.

According to Iconic, proceeds from the financing will be used to advance development of lead molecule ICON-1 in retinal diseases as well as begin clinical trials in ocular melanoma, Iconic's first oncology indication.

Iconic is a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer.

The team advising Iconic included Mark Weeks, Anita Vasudevan, Daniel Elefant, Mike Tuscan and Marya Postner.

Cooley is advising FibroGen on its $167.7 million initial public offering. With a $1.04 billion valuation, this is the largest biotech IPO by market cap since 2002.

FibroGen is a biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer and other serious unmet medical needs. The company now trades on the Nasdaq Global Market under the symbol "FGEN."

Reston, Va. – Cooley advised the underwriters on T2 Biosystems' initial public offering. T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The company now trades on the Nasdaq Global Stock Market under the symbol "TTOO."

Goldman Sachs and Morgan Stanley acted as joint book running managers for the offering. Leerink Partners and Janney Montgomery Scott acted as co-managers for the offering.

Thus far in 2014, Cooley has advised on 75 public offerings, including 38 completed IPOs.